Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP

Prostate

Volumn 52, Issue 1, 2002, Pages 1-11

  Rokhlin, Oskar W ^a   Guseva, Natalya V ^a   Tagiyev, Agshin F ^a   Glover, Rebecca A ^a   Cohen, Michael B ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cell death; PI3K Akt pathway; Prostatic neoplasms; TRAIL

Indexed keywords

CALCEIN; CASPASE 8; HYGROMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; ENZYME ACTIVATION; ENZYME RELEASE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANDROSTADIENES; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARRIER PROTEINS; CASPASE 8; CASPASE 9; CASPASES; CINNAMATES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITORS; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; HYGROMYCIN B; MALE; MEMBRANE GLYCOPROTEINS; NUCLEAR PROTEINS; PEPTIDE HYDROLASES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036604109     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10074     Document Type: Article

References (64)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Induction of apoptosis by Apo-2, a new member of the tumor necrosis factor receptor family
3. The receptor for the cytotoxic ligand TRAIL
4. An antagonist decoy receptor and a new death domain-containing receptor for TRAIL
5. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
6. TRICK2, a new alternatively spliced receptor that tranduces the cytotixic signal from TRAIL
7. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
8. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene
9. FADD/MORT 1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
10. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
11. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
12. Lymphocyte inhibitor of TRAIL: A new receptor protecting lymphocytes from the death ligand TRAIL
13. A novel receptor for Apo2L/TRAIL contains a truncated death domain
14. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling
15. TRAIL: A molecule with multiple receptors and control mechanisms
16. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
17. Functional analysis of TRAIL receptors using monoclonal antibodies
18. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma
19. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
20. Adenoviral-mediated transfer of the TNF-related apoptosis inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
21. Implication of multiple mechanisms in apoptosis induced by synthetic retinoid CD437 in human prostate carcinoma cells
22. Tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells
23. Preatreatment with paclitaxel enhances Apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels
24. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis
25. Fas-mediated apoptosis in human prostatic carcinoma cell lines
26. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
27. CD95 (APO-1/Fas)-associating signalling proteins
28. Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7
29. p53 is involved in tumor necrosis factor-a-induced apoptosis in the human prostatic carcinoma cell line LNCaP
30. Oncogene-dependent apoptosis in extracts from drug-resistant cells
31. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
32. Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines
33. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B
34. The phosphatidylinositol 3′-kinase pathway is a dominant growth-factor-activated cell survival pathway in LNCaP human prostate carcinoma cells
35. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines
36. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor
37. Prevention of cell death induced by tumor necrosis factor a in LNCaP cells by over-expression of sulfated glycoprotein-2 (clusterin)
38. TNF mediated cytotoxicity and resistance in human prostate cancer cell lines
39. Inhibition of human caspases by peptide-based and macromolecular inhibitors
40. Cellular survival: A play in three Akts
41. TRAIL causes cleavage of Bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells
42. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE
43. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles
44. p53 oncogene mutations in three human prostate cancer cell lines
45. Surfing the p53 network
46. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
47. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells
48. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor nacrosis factor-related apoptosis-inducing ligand in vitro and in vivo
49. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan
50. Molecular determinants of response to TRAIL in killing of normal and cancer cells
51. Caspase activation without death
52. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
53. Induction of apoptosis in AK-5 tumor cells by a serum factor from tumor rejecting animals: Cytochrome c release independent of Bcl-2 and caspases
54. Regulation of cell death protease caspase-9 by phosphorylation
55. Cleavage of CDK inhibitor p21/Cipl/Waf by caspases is an early event during DNA damageinduced apoptosis
56. Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAFI proteolysis in ME-180 cells
57. Caspase 3 inactivation to supress Fas-mediated apoptosis: Identification of binding domain with p21 and ILP and inactivation machinery by p21
58. Procaspase 3/p21 complex formation to resist Fasmediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A
59. p21/WAFI/CIPI inhibits initiator caspase cleavage by TRAIL death receptor DR4
60. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21/WAF1/CIP1/SD11 induced by cisplatin and paclitaxel
61. Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptosic signals
62. Mdm2 promotes the rapid degradation of p53
63. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis